Publications by authors named "P Gonzalez-Latapi"
Long-term longitudinal data on outcomes in sporadic Parkinson's Disease are limited, especially from cohorts with extensive biological characterization. Recent advances in biomarkers characterization of Parkinson's Disease necessitate an updated examination of long-term progression within contemporary cohorts like the Parkinson's Progression Markers Initiative, which enrolled individuals within 2 years of clinical diagnosis of Parkinson's Disease. Our study leverages the Neuronal Synuclein Disease framework, which defines the disease based on biomarker assessed presence of neuronal alpha-synuclein and dopamine deficit, rather than based on conventional clinical diagnostic criteria.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates LRRK2-associated parkinsonism cases, focusing on the presence or absence of pathologic alpha-synuclein aggregates, which is critical for developing treatments.
- Results indicate that those without alpha-synuclein aggregates are generally older, have a similar diagnosis duration, and experience different motor and olfactory symptoms compared to those with aggregates.
- The analysis highlights the need for further understanding of the clinical features and biological differences to enhance therapeutic strategies for Parkinson's disease.
Purpose Of Review: In recent decades, epidemiological understanding of Parkinson disease (PD) has evolved significantly. Major discoveries in genetics and large epidemiological investigations have provided a better understanding of the genetic, behavioral, and environmental factors that play a role in the pathogenesis and progression of PD. In this review, we provide an epidemiological update of PD with a particular focus on advances in the last five years of published literature.
View Article and Find Full Text PDFObjective: To characterize DNA methylation (DNAm) differences between sporadic Parkinson's disease (PD) and healthy control (HC) individuals enrolled in the Parkinson's Progression Markers Initiative (PPMI).
Methods: Using whole blood, we characterized longitudinal differences in DNAm between sporadic PD patients (n = 196) and HCs (n = 86) enrolled in PPMI. RNA sequencing (RNAseq) was used to conduct gene expression analyses for genes mapped to differentially methylated cytosine-guanine sites (CpGs).